» Articles » PMID: 31001055

A Clinical Study of a Standardized Extract of Leaves of (Roxb Ex DC) in Postmenopausal Osteoporosis

Overview
Date 2019 Apr 20
PMID 31001055
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Context: had shown anti-osteoporotic and fracture-healing activities in animal models of postmenopausal osteoporosis (PMO). Standardized extract of leaves of (SEL-Ds) was clinically evaluated for osteoporosis.

Aims: To investigate the anti-osteoporotic activity of in PMO by dual-energy X-ray absorptiometry (DXA), biochemical markers, and effect on clinical profile. Tolerability was assessed by organ function tests and adverse events.

Settings And Design: An open-labeled prospective clinical study in ambulant settings was conducted at the menopausal health-care facility of a women's hospital.

Materials And Methods: Thirty women (45-69 years) were enrolled for this 1-year study. Evaluations were basally, fortnightly twice, and three monthly four times. SEL-Ds (300 mg) twice daily was administered orally. Calcium (250 mg) and Vitamin D (200 IU) were given twice a day. The efficacy of SEL-Ds was assessed by DXA-scan (spine, femur), by biochemical markers, alkaline phosphatase (ALP), tumor necrosis factor-alpha (TNF-α), and anti-inflammatory marker high-sensitivity C-reactive protein (hs-CRP). Baseline symptom changes and adverse events were carefully recorded.

Statistical Analysis: Summary statistics (n, mean, standard deviation, median, and maximum and minimum values) of changes from baseline values and Student's "t-" test for values were used.

Results And Discussion: SEL-Ds was well tolerated at given dose for 1 year. Anti-osteoporotic and anti-inflammatory activities of SEL-Ds were demonstrated by reduction in TNF-α (12.04 ± 2.81-2.35 ± 1.08 pg/ml), ALP (208.75 ± 45.88-154.52 ± 37.25 IU/L), and hs-CRP (6.1 ± 0.77-3.9 ± 0.47 mg/L). BMD-score on DXA-scan also remained unchanged at majority of the bone locations (increased 13/75, unchanged 51/75, and decreased 08/75).

Conclusions: has demonstrated anti-osteoporotic and anti-inflammatory activities as indicated by decline in circulating TNF-α along with concurrent reduction in ALP. The nondecline in BMD index in the majority confirms the anti-osteoporotic activity.

Citing Articles

Report: Council for Ayurveda Research - Industry Roundtable and Global Consortium for Collaborative Research in Ayurveda, 2021.

Shah P, Gupta M, Baranwal V, Seetharaman M J Ayurveda Integr Med. 2022; 13(3):100595.

PMID: 35933941 PMC: 9684697. DOI: 10.1016/j.jaim.2022.100595.


A Convergent and Multidisciplinary Integration for Research in Menopause.

Ashok B, Rama A J Midlife Health. 2022; 13(1):5-8.

PMID: 35707308 PMC: 9190962. DOI: 10.4103/jmh.jmh_65_22.


Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis.

Wang Y, Xie J, Ai Z, Su J Int J Nanomedicine. 2019; 14:7839-7849.

PMID: 31576127 PMC: 6769031. DOI: 10.2147/IJN.S213724.

References
1.
Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A . Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000; 275(7):4858-64. DOI: 10.1074/jbc.275.7.4858. View

2.
Cenci S, Weitzmann M, Roggia C, Namba N, Novack D, Woodring J . Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 2000; 106(10):1229-37. PMC: 381439. DOI: 10.1172/JCI11066. View

3.
Hajare S, Chandra S, Sharma J, Tandan S, Lal J, Telang A . Anti-inflammatory activity of Dalbergia sissoo leaves. Fitoterapia. 2001; 72(2):131-9. DOI: 10.1016/s0367-326x(00)00272-0. View

4.
Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

5.
Nanes M . Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene. 2003; 321:1-15. DOI: 10.1016/s0378-1119(03)00841-2. View